Your browser doesn't support javascript.
loading
T cell receptor ß repertoires in patients with COVID-19 reveal disease severity signatures.
Xu, Jing; Li, Xiao-Xiao; Yuan, Na; Li, Chao; Yang, Jin-Gang; Cheng, Li-Ming; Lu, Zhong-Xin; Hou, Hong-Yan; Zhang, Bo; Hu, Hui; Qian, Yu; Liu, Xin-Xuan; Li, Guo-Chao; Wang, Yue-Dan; Chu, Ming; Dong, Chao-Ran; Liu, Fan; Ge, Qing-Gang; Yang, Yue-Jin.
Afiliación
  • Xu J; State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital & National Center for Cardiovascular Diseases, Beijing, China.
  • Li XX; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Yuan N; Department of Pharmacy and Department of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
  • Li C; CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  • Yang JG; University of Chinese Academy of Sciences, Beijing, China.
  • Cheng LM; Department of Pharmacy and Department of Intensive Care Unit, Peking University Third Hospital, Beijing, China.
  • Lu ZX; State Key Laboratory of Cardiovascular Diseases, Fuwai Hospital & National Center for Cardiovascular Diseases, Beijing, China.
  • Hou HY; Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
  • Zhang B; Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hu H; Department of Medical Laboratory, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Qian Y; Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Liu XX; Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Li GC; Department of Medical Laboratory, the Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wang YD; CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  • Chu M; China National Center for Bioinformation, Beijing, China.
  • Dong CR; University of Chinese Academy of Sciences, Beijing, China.
  • Liu F; CAS Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China.
  • Ge QG; China National Center for Bioinformation, Beijing, China.
  • Yang YJ; University of Chinese Academy of Sciences, Beijing, China.
Front Immunol ; 14: 1190844, 2023.
Article en En | MEDLINE | ID: mdl-37475855
Background: The immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are crucial in maintaining a delicate balance between protective effects and harmful pathological reactions that drive the progression of coronavirus disease 2019 (COVID-19). T cells play a significant role in adaptive antiviral immune responses, making it valuable to investigate the heterogeneity and diversity of SARS-CoV-2-specific T cell responses in COVID-19 patients with varying disease severity. Methods: In this study, we employed high-throughput T cell receptor (TCR) ß repertoire sequencing to analyze TCR profiles in the peripheral blood of 192 patients with COVID-19, including those with moderate, severe, or critical symptoms, and compared them with 81 healthy controls. We specifically focused on SARS-CoV-2-associated TCR clonotypes. Results: We observed a decrease in the diversity of TCR clonotypes in COVID-19 patients compared to healthy controls. However, the overall abundance of dominant clones increased with disease severity. Additionally, we identified significant differences in the genomic rearrangement of variable (V), joining (J), and VJ pairings between the patient groups. Furthermore, the SARS-CoV-2-associated TCRs we identified enabled accurate differentiation between COVID-19 patients and healthy controls (AUC > 0.98) and distinguished those with moderate symptoms from those with more severe forms of the disease (AUC > 0.8). These findings suggest that TCR repertoires can serve as informative biomarkers for monitoring COVID-19 progression. Conclusions: Our study provides valuable insights into TCR repertoire signatures that can be utilized to assess host immunity to COVID-19. These findings have important implications for the use of TCR ß repertoires in monitoring disease development and indicating disease severity.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Immunol Año: 2023 Tipo del documento: Article